Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToFingo2: Gilenya in RRMS Patients Switching From Natalizumab
NCT02325440Phase 4Unknown
- Sponsor
- Universitätsklinikum Münster
- Start
- Mar 2014
- Primary completion
- Apr 2016
- Countries
- 1
01
Overview
A Phase 4 trial of fingolimod in multiple sclerosis (MS), sponsored by Universitätsklinikum Münster. Status: unknown.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02325440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325440.